Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

HIF-1-dependent stromal adaptation to ischemia mediates in vivo tumor radiation resistance.

Schwartz DL, Bankson J, Bidaut L, He Y, Williams R, Lemos R, Thitai AK, Oh J, Volgin A, Soghomonyan S, Yeh HH, Nishii R, Mukhopadhay U, Alauddin M, Mushkudiani I, Kuno N, Krishnan S, Bornman W, Lai SY, Powis G, Hazle J, Gelovani J.

Mol Cancer Res. 2011 Mar;9(3):259-70. doi: 10.1158/1541-7786.MCR-10-0469. Epub 2011 Mar 1.

2.

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, Lemos R, Oh J, Volgin A, Soghomonyan S, Nishii R, Alauddin M, Mukhopadhay U, Peng Z, Bornmann W, Gelovani J.

Mol Cancer Ther. 2009 Apr;8(4):947-58. doi: 10.1158/1535-7163.MCT-08-0981.

3.

The suppression of hypoxia-inducible factor and vascular endothelial growth factor by siRNA does not affect the radiation sensitivity of multicellular tumor spheroids.

Zou Y, Cheng C, Omura-Minamisawa M, Kang Y, Hara T, Guan X, Inoue T.

J Radiat Res. 2010;51(1):47-55. Epub 2009 Dec 4.

4.

Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.

Schwartz DL, Bankson JA, Lemos R Jr, Lai SY, Thittai AK, He Y, Hostetter G, Demeure MJ, Von Hoff DD, Powis G.

Mol Cancer Ther. 2010 Jul;9(7):2057-67. doi: 10.1158/1535-7163.MCT-09-0768. Epub 2010 Jun 29.

5.

NADPH oxidase subunit 4 mediates cycling hypoxia-promoted radiation resistance in glioblastoma multiforme.

Hsieh CH, Wu CP, Lee HT, Liang JA, Yu CY, Lin YJ.

Free Radic Biol Med. 2012 Aug 15;53(4):649-58. doi: 10.1016/j.freeradbiomed.2012.06.009. Epub 2012 Jun 16.

PMID:
22713363
6.

Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice.

Serganova I, Doubrovin M, Vider J, Ponomarev V, Soghomonyan S, Beresten T, Ageyeva L, Serganov A, Cai S, Balatoni J, Blasberg R, Gelovani J.

Cancer Res. 2004 Sep 1;64(17):6101-8.

7.

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.

Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, McKenna WG, Muschel RJ, Hiraoka M.

Nat Commun. 2012 Apr 17;3:783. doi: 10.1038/ncomms1786. Erratum in: Nat Commun. 2013;4. doi:10.1038/ncomms3314.

8.

Radiation sensitivity assay with a panel of patient-derived spheroids of small cell carcinoma of the cervix.

Nakajima A, Endo H, Okuyama H, Kiyohara Y, Kimura T, Kamiura S, Hiraoka M, Inoue M.

Int J Cancer. 2015 Jun 15;136(12):2949-60. doi: 10.1002/ijc.29349. Epub 2014 Dec 11.

9.

HIF-1 and NDRG2 contribute to hypoxia-induced radioresistance of cervical cancer Hela cells.

Liu J, Zhang J, Wang X, Li Y, Chen Y, Li K, Zhang J, Yao L, Guo G.

Exp Cell Res. 2010 Jul 15;316(12):1985-93. doi: 10.1016/j.yexcr.2010.02.028. Epub 2010 Mar 3.

PMID:
20206160
10.

Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation.

Helbig L, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, Pruschy M, Baumann M, Yaromina A, Zips D.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):159-66. doi: 10.1016/j.ijrobp.2013.09.047.

PMID:
24331663
11.

Glucagon-induced angiogenesis and tumor growth through the HIF-1-VEGF-dependent pathway in hyperglycemic nude mice.

Wang Y, Zhu YD, Gui Q, Wang XD, Zhu YX.

Genet Mol Res. 2014 Sep 5;13(3):7173-83. doi: 10.4238/2014.September.5.3.

12.

Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging.

Øvrebø KM, Gulliksrud K, Mathiesen B, Rofstad EK.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):255-61. doi: 10.1016/j.ijrobp.2011.04.008.

PMID:
21816291
13.

How can we overcome tumor hypoxia in radiation therapy?

Harada H.

J Radiat Res. 2011;52(5):545-56. Review.

14.

Raising the bar: how HIF-1 helps determine tumor radiosensitivity.

Moeller BJ, Dewhirst MW.

Cell Cycle. 2004 Sep;3(9):1107-10. Epub 2004 Sep 20. Review.

PMID:
15326390
15.

Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice.

Hsieh CH, Kuo JW, Lee YJ, Chang CW, Gelovani JG, Liu RS.

J Nucl Med. 2009 Dec;50(12):2049-57. doi: 10.2967/jnumed.108.061234. Epub 2009 Nov 12.

16.

Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.

Shi M, Guo XT, Shu MG, Chen FL, Li LW.

Med Hypotheses. 2007;69(1):33-5. Epub 2007 Feb 5.

PMID:
17280792
17.

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1.

Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL.

Mol Cell Biol. 1996 Sep;16(9):4604-13.

19.

Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts.

Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, Kantsevoy SV, Dang LH.

Cancer Res. 2006 Feb 1;66(3):1684-936.

20.

Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.

Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML.

J Natl Cancer Inst. 2006 Jul 19;98(14):984-95.

PMID:
16849681

Supplemental Content

Support Center